Scheen A J
Université de Liège.
Rev Med Liege. 1998 Jun;53(6):374-7.
Atorvastatin, commercialized by the pharmaceutical companies Parke-Davis and Pfizer under the trade name Lipitor, is a new statin acting as a potent hypolipidaemic drug. By inhibiting HMG-CoA reductase, the key-enzyme of cellular synthesis of cholesterol, it increases the expression of LDL receptors and promotes the hepatic extraction of circulating LDL. It has a more potent action than other available statins, both on LDL cholesterol and triglyceride levels. Atorvastatin is indicated, after diet failure, in the treatment of primary hypercholesterolaemia or combined hyperlipidaemia. Lipitor is available as tablets of 10 and 20 mg. The usual doses is 10 mg once a day, to be increased up to 20 mg/day if necessary. In rare severe cases, the doses may be increased up to 80 mg/day.
阿托伐他汀由制药公司帕克-戴维斯和辉瑞以商品名立普妥商业化销售，是一种新型他汀类药物，用作强效降血脂药。通过抑制细胞胆固醇合成的关键酶HMG-CoA还原酶，它可增加低密度脂蛋白（LDL）受体的表达，并促进肝脏对循环中LDL的摄取。它对LDL胆固醇和甘油三酯水平的作用比其他现有他汀类药物更强。在饮食治疗无效后，阿托伐他汀适用于原发性高胆固醇血症或混合性高脂血症的治疗。立普妥有10毫克和20毫克片剂。常用剂量为每日10毫克，必要时可增至每日20毫克。在罕见的严重情况下，剂量可增至每日80毫克。
